CYBN Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Cybin Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.00 |
| 52 Week High | US$27.36 |
| 52 Week Low | US$9.25 |
| Beta | 0.88 |
| 11 Month Change | 4.90% |
| 3 Month Change | 11.21% |
| 1 Year Change | -38.31% |
| 33 Year Change | -79.00% |
| 5 Year Change | n/a |
| Change since IPO | -58.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| CYBN | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -2.0% | -4.5% | 1.7% |
| 1Y | -38.3% | -22.5% | 24.0% |
Return vs Industry: CYBN underperformed the Canadian Pharmaceuticals industry which returned -22.5% over the past year.
Return vs Market: CYBN underperformed the Canadian Market which returned 24% over the past year.
Price Volatility
| CYBN volatility | |
|---|---|
| CYBN Average Weekly Movement | 11.9% |
| Pharmaceuticals Industry Average Movement | 11.9% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.6% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: CYBN has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: CYBN's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 50 | Doug Drysdale | www.cybin.com |
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers.
Cybin Inc. Fundamentals Summary
| CYBN fundamental statistics | |
|---|---|
| Market cap | CA$299.36m |
| Earnings (TTM) | -CA$123.69m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.4x
P/E RatioIs CYBN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYBN income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$123.69m |
| Earnings | -CA$123.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.18 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CYBN perform over the long term?
See historical performance and comparison